普萊柯(603566.SH):擬放棄中科基因增資的優先認購權
格隆匯 8 月 7日丨普萊柯(603566.SH)公佈,參股公司北京中科基因技術有限公司(“中科基因”)為引進戰略投資者,優化股權及治理結構,擬按照10.8億元的投前估值進行股權融資,融資金額為不超過12623.3766萬元,其中外部股權融資金額不超過1.2億元。
關聯方誠通中信農業結構調整投資基金(有限合夥)(“誠通中信”)擬認購不超過8000萬元,公司及中科基因控股股東餘江縣匯澤投資管理中心(有限合夥)(“餘江匯澤”)擬放棄此次增資優先認購權,上述交易構成關聯交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.